Cover Image
市場調查報告書

Diabetology Limited:產品平台分析

Diabetology Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293994
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Diabetology Limited:產品平台分析 Diabetology Limited - Product Pipeline Review - 2015
出版日期: 2015年05月20日 內容資訊: 英文 27 Pages
簡介

Diabetology Limited是Proxima Concepts Limited的子公司,是總公司設立於英國的生物製藥企業。從事治療糖尿病用之口服給藥系統的開發,製造及銷售。開發平台擁有第二型糖尿病的口服治療藥物Capsulin OAD,及抑制肝臟放出葡萄糖提高胰島素敏銳度及β細胞功能的GLP-1 analogue等產品。

本報告提供Diabetology Limited 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

目錄

Diabetology Limited 基本資料

  • Diabetology Limited 概要
  • 主要資訊
  • 企業資料

Diabetology Limited :R&D概要

  • 主要的治療範圍

Diabetology Limited :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Diabetology Limited :開發中產品概況

  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Diabetology Limited :藥物簡介

  • Capsulin OAD
  • insulin human
  • Combulin
  • Oral C-Peptide Analogs
  • Oral GLP-1
  • Oral GLP-1 Analogs
  • Oral Insulin Analogs

Diabetology Limited :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Diabetology Limited :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07059CDB

Summary

Global Markets Direct's, 'Diabetology Limited - Product Pipeline Review - 2015', provides an overview of the Diabetology Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Diabetology Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Diabetology Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Diabetology Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Diabetology Limited's pipeline products

Reasons to buy

  • Evaluate Diabetology Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Diabetology Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Diabetology Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Diabetology Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Diabetology Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Diabetology Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Diabetology Limited Snapshot
    • Diabetology Limited Overview
    • Key Information
    • Key Facts
  • Diabetology Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Diabetology Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Diabetology Limited - Pipeline Products Glance
    • Diabetology Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Diabetology Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Diabetology Limited - Drug Profiles
    • Capsulin OAD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • insulin human
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Combulin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oral C-Peptide Analogs
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oral GLP-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oral GLP-1 Analogs
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oral Insulin Analogs
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Diabetology Limited - Pipeline Analysis
  • Diabetology Limited - Pipeline Products by Target
  • Diabetology Limited - Pipeline Products by Route of Administration
  • Diabetology Limited - Pipeline Products by Molecule Type
  • Diabetology Limited - Pipeline Products by Mechanism of Action
  • Diabetology Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Diabetology Limited, Key Information
  • Diabetology Limited, Key Facts
  • Diabetology Limited - Pipeline by Indication, 2015
  • Diabetology Limited - Pipeline by Stage of Development, 2015
  • Diabetology Limited - Monotherapy Products in Pipeline, 2015
  • Diabetology Limited - Phase II, 2015
  • Diabetology Limited - Preclinical, 2015
  • Diabetology Limited - Pipeline by Target, 2015
  • Diabetology Limited - Pipeline by Route of Administration, 2015
  • Diabetology Limited - Pipeline by Molecule Type, 2015
  • Diabetology Limited - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Diabetology Limited - Pipeline by Top 10 Indication, 2015
  • Diabetology Limited - Pipeline by Stage of Development, 2015
  • Diabetology Limited - Monotherapy Products in Pipeline, 2015
  • Diabetology Limited - Pipeline by Top 10 Target, 2015
  • Diabetology Limited - Pipeline by Top 10 Route of Administration, 2015
  • Diabetology Limited - Pipeline by Top 10 Molecule Type, 2015
  • Diabetology Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top